02196 復星醫藥
按盘价 
14.900 -0.220 (-1.455%) 盈利能力分析
| 2022/12 | 2021/12 | 2020/12 | 2019/12 | 2018/12 | |
| 资产回报率 (%) | 3.730% | 5.347% | 4.587% | 4.533% | 4.090% |
| 股东资金回报率 (%) | 8.933% | 12.431% | 10.652% | 11.118% | 10.182% |
| 资本运用回报率 (%) | 5.063% | 7.397% | 6.234% | 5.665% | 5.151% |
边际利润分析
| 2022/12 | 2021/12 | 2020/12 | 2019/12 | 2018/12 | |
| 毛利率 (%) | 47.115% | 47.947% | 54.469% | 59.339% | 58.059% |
| 未计利息、税项、折旧及摊销前利润率 (%) | 13.519% | 17.473% | 18.257% | 19.384% | 17.648% |
| 税前边际利润率 (%) | 10.455% | 15.548% | 15.508% | 15.942% | 14.484% |
| 纯利率 (%) | 8.530% | 12.167% | 12.143% | 11.700% | 10.957% |
变现能力分析
| 2022/12 | 2021/12 | 2020/12 | 2019/12 | 2018/12 | |
| 流动比率 (X) | 1.059 X | 1.038 X | 1.009 X | 1.170 X | 1.004 X |
| 速动比率 (X) | 0.853 X | 0.851 X | 0.801 X | 0.944 X | 0.821 X |
财务杠杆分析
| 2022/12 | 2021/12 | 2020/12 | 2019/12 | 2018/12 | |
| 总负债 / 总资产比率 (%) | 49.532% | 48.179% | 45.082% | 48.533% | 52.428% |
| 总债项 / 总资产比率 (%) | 28.064% | 27.157% | 28.861% | 28.517% | -- |
| 净债项 / 总资产比率 (%) | 12.901% | 16.093% | 16.949% | 15.984% | -- |
| 总债项 / 股东资金比率 (%) | 67.502% | 64.702% | 65.341% | 68.144% | -- |
| 长期债项 / 股东资金比率 (%) | 28.844% | 24.777% | 24.644% | 40.800% | -- |
| 净债项 / 股东资金比率 (%) | 31.031% | 38.341% | 38.373% | 38.195% | -- |
| 净现金 / (债项) ($) | (138.18亿) | (150.06亿) | (141.74亿) | (121.58亿) | -- |
| 每股净现金 / (债项) ($) | (5.171) | (5.855) | (5.531) | (4.744) | -- |
| 总债项 / 资本运用比率 (%) | 40.723% | 39.611% | 41.078% | 36.997% | -- |
| 利息盈利率 (X) | 5.753 X | 8.346 X | 6.310 X | 5.211 X | 4.850 X |
营运效率分析
| 2022/12 | 2021/12 | 2020/12 | 2019/12 | 2018/12 | |
| 存货周转率日数 (日) | 97.316日 | 95.945日 | 120.971日 | 114.273日 | -- |
| 应收贸易帐周转率日数 (日) | 56.897日 | 50.964日 | 56.963日 | 57.496日 | -- |
| 应付贸易帐周转率日数 (日) | 47.270日 | 39.223日 | 34.405日 | 30.411日 | -- |
| 备注： | 实时报价更新时间为13/03/2025 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) (千) | RMB 1,224,799 |
| 增长率 | -31.332% |
| 每股盈利/(亏损) | RMB 0.460 |
| 每股账面资产净值 (¥) | RMB 17.561 |